Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial

Infinity Pharmaceuticals Inc INFI presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS). 

  • MARIO-3 Phase 2 trial is evaluating eganelisib in combination with Roche Holdings AG's RHHBY atezolizumab (Tecentriq) and Bristol-Myers Squibb Co's BMY Abraxane (nab-paclitaxel) in frontline metastatic triple-negative breast cancer (TNBC).
  • The data update includes 50 patients enrolled and 44 evaluable as of the October 2 data cutoff date, with a median duration of follow-up of 9.9 months.
  • Of evaluable patients, tumor reduction was observed in 92.8% of patients with PD-L1 positive tumors (13/14) and 85.2% of patients with PD-L1 negative tumors (22/27).
  • Median Progression-free survival (PFS) in PD-L1(+) tumors was 11.0 months, a 47% improvement compared to the 7.5 months reported for atezolizumab and nab-paclitaxel alone.
  • In patients with PD-L1(-) tumors, median PFS was 7.3 months, a 30% improvement compared to the 5.6 months reported for atezolizumab and nab-paclitaxel alone.
  • Price Action: INFI shares are down 0.22% at $2.32 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralbreast cancerBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!